<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01032343</url>
  </required_header>
  <id_info>
    <org_study_id>AICR 08-0131</org_study_id>
    <secondary_id>UKCRN 6873</secondary_id>
    <nct_id>NCT01032343</nct_id>
  </id_info>
  <brief_title>An Immunonutritional Approach to the Prevention of Skin Cancer</brief_title>
  <official_title>The Effect of Omega-3 Polyunsaturated Fatty Acids on UV-induced Immunosuppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Manchester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Skin cancer incidence continues to rise and ultraviolet radiation (UVR) in sunlight is the
      principal cause. Solar UVR can promote cancer development through its ability to suppress the
      immune system. The purpose of this study is to determine whether dietary supplementation with
      omega-3 polyunsaturated fatty acids can protect human skin from UVR-induced
      immunosuppression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Skin cancer is one of the most common human cancers with a rising incidence and considerable
      negative impact on human health. Exposure to ultraviolet radiation (UVR) in sunlight is the
      major aetiological factor in skin cancer initiation and progression. Human case-control
      studies have reported an inverse relationship between dietary fish or omega-3 polyunsaturated
      fatty acid (PUFA) intake and occurrence of non-melanoma skin cancer. Omega-3 PUFA have the
      potential to reduce the risk of photocarcinogenesis primarily by their ability to reduce
      production of prostaglandin E2 and consequently photoimmunosuppression. To date, no studies
      have assessed the impact of omega-3 PUFA on skin photoimmunosuppression in humans.

      OBJECTIVE: To examine the potential of dietary omega-3 PUFA to protect against UVR-induced
      cutaneous immunosuppression in humans.

      STUDY DESIGN: A double-blind randomised controlled nutritional study in 64 healthy human
      volunteers with nickel sensitivity. Volunteers will receive 3 months dietary supplementation
      with either omega-3 PUFA (n=32) or gelatine (n=32) both provided in identical gelatine
      capsules.

      The aim is to quantify the influence of omega-3 PUFA on:

        1. UVR-induced suppression of clinical contact hypersensitivity (CHS) responses

        2. UVR-induced modulation of epidermal Langerhans cell trafficking

        3. UVR-induced modulation of levels of immunoregulatory mediators
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of suppression of nickel-induced contact hypersensitivity</measure>
    <time_frame>3 months</time_frame>
    <description>Measurement of the erythema of nickel-induced eczema using a reflectance instrument</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intergroup comparison of cytokine and eicosanoid levels and Langerhans cell numbers</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of susceptibility to photoimmunosuppression in all subjects with their erythrocyte omega-3:omega-6 PUFA ratio</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of susceptibility to photoimmunosuppression with cytokine and eicosanoid levels and Langerhans cell numbers</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Skin Cancer</condition>
  <arm_group>
    <arm_group_label>Omega-3 PUFA capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gelatine capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 PUFA</intervention_name>
    <description>One capsule (4g omega-3 PUFA) daily for 3 months</description>
    <arm_group_label>Omega-3 PUFA capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gelatine</intervention_name>
    <description>One capsule daily for 3 months</description>
    <arm_group_label>Gelatine capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-menopausal females

          -  Sun-reactive skin type I / II

          -  Reporting allergy to jewellery with nickel content

        Exclusion Criteria:

          -  History of atopy

          -  History of skin cancer

          -  History of a photosensitivity disorder

          -  Sunbathing (including sunbeds) in the last 3 months

          -  Pregnancy

          -  History of cardiac disease

          -  Taking photoactive medicine

          -  Not able to eat fish or gelatine

          -  Taking fish oil supplements prior to the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lesley E Rhodes, MBBS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manchester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.staffnet.manchester.ac.uk/volunteering/display/index.htm?id=149716</url>
    <description>Study recruitment information</description>
  </link>
  <results_reference>
    <citation>Pilkington SM, Massey KA, Bennett SP, Al-Aasswad NM, Roshdy K, Gibbs NK, Friedmann PS, Nicolaou A, Rhodes LE. Randomized controlled trial of oral omega-3 PUFA in solar-simulated radiation-induced suppression of human cutaneous immune responses. Am J Clin Nutr. 2013 Mar;97(3):646-52. doi: 10.3945/ajcn.112.049494. Epub 2013 Jan 30.</citation>
    <PMID>23364005</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2009</study_first_submitted>
  <study_first_submitted_qc>December 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2009</study_first_posted>
  <last_update_submitted>August 21, 2013</last_update_submitted>
  <last_update_submitted_qc>August 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Manchester</investigator_affiliation>
    <investigator_full_name>Lesley Rhodes</investigator_full_name>
    <investigator_title>Professor of Experimental Dermatology</investigator_title>
  </responsible_party>
  <keyword>Immunosuppression</keyword>
  <keyword>Ultraviolet radiation</keyword>
  <keyword>Nickel</keyword>
  <keyword>Contact hypersensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

